Posts

Showing posts from 2025

Natto vs Nattokinase vs Nattozimes: What's the Difference?

Image
Marketing geniuses have positioned soy as the wonder health alternative to virtually everything. In most supermarkets, you’ll find soy milk, soy protein, soybean oil, soy lecithin and even soy soap. Unfortunately, though, many forms of soy are not necessarily as healthy as food manufacturers would like you to believe. The problem is the soy you see in all these foods is not the traditionally grown crop of Japan. In fact, the majority of soy that you find in in grocery stores is actually genetically modified (GMO), produced in a different way and doesn’t yield the same nutritional benefits. However, when you ferment soybeans you have a completely different product that boasts an entirely separate set of nutrients, which is why when it comes to soy, the safest and best way to consume it is through fermented foods like miso, tempeh or natto. So what is natto, and how can it impact your health? Let’s dig in. What is Natto? Natto is a popular food in Japan, and is made by fermenting soybean...

Triple G-Agonists (Retatrutide and Beyond): A Continued Home Run for Obesity in 2025

Image
Introduction The buzz around hormone-based obesity therapies, ignited at the 2023 American Diabetes Association (ADA) Scientific Sessions, has only intensified by 2025. Retatrutide, Eli Lilly's triple-hormone-receptor agonist, led the charge with phase 2 results showing 24% mean weight loss over 48 weeks in non-diabetic adults with obesity ( aestheticsadvisor.com ). Now in phase 3 (TRIUMPH program), with topline data expected Q4 2025 and potential FDA approval by 2027, retatrutide exemplifies the triple G-agonist class's promise. Meanwhile, competitors like Novo's UBT251 (15.4% loss in 12 weeks phase 1b) and oral candidates from Protagonist Therapeutics signal a transformative era, potentially outpacing dual agonists like tirzepatide.   Source:  eClinicalMedicine 2024 Hormonal Responses and Background Nutrient sensing triggers a symphony of hormones—insulin, GLP-1, GIP, PYY, amylin—that curb appetite, boost insulin, and ramp up metabolism. GLP-1 agonists revolutionized T2D ...

Labels

Show more

Archive

Show more